Spiropiperidine Compounds for Selective GPR40 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments, particularly for type 2 diabetes, often come with adverse effects such as hypoglycemia, liver damage, and weight gain due to PPAR gamma activity, and there is a need for a more selective and safer pharmacological mechanism to modulate insulin secretion.
Innovation Solution
Development of compounds that selectively activate GPR40, a receptor primarily expressed in pancreatic beta cells, without detectable PPAR activity, using specific chemical structures that are potent activators of GPR40, thereby providing a unique treatment option for type 2 diabetes with a desirable safety profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PPAR gamma activity is used to treat diabetes, then insulin sensitivity is improved, but adverse effects such as hypoglycemia, liver damage, and weight gain occur
Solution Approach 1:
The patent segments the therapeutic effect into two distinct pathways: GPR40 activation for insulin secretion enhancement and PPAR gamma avoidance to prevent adverse effects. This segmentation allows selective targeting of beneficial effects while eliminating harmful ones through structural design of compounds that specifically activate GPR40 without PPAR gamma activity.
Solution Approach 2:
The invention extracts the desired insulin secretion effect from the PPAR gamma pathway and relocates it to the GPR40 pathway. By designing compounds that selectively activate GPR40, the patent separates the beneficial insulinotropic effect from the harmful PPAR gamma-mediated side effects, achieving treatment efficacy without adverse events.
2Object-affected harmful factors
If GPR40 is selectively activated without PPAR gamma activity, then safety profile is improved, but compound structural complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific heteroatom substitutions (nitrogen, oxygen, sulfur) at particular positions within the spiro compound structure. These localized structural modifications confer selective GPR40 activation while maintaining overall structural simplicity, achieving safety improvement without excessive complexity.
Solution Approach 2:
The invention changes key structural parameters by incorporating heteroatoms (N, O, S) at specific positions in the spiro compound framework. This parameter modification transforms the compound's receptor selectivity, enabling GPR40 activation without PPAR gamma activity, thus improving safety while controlling complexity through targeted structural changes.
3Speed
If hydrocarbon spiro group free of heteroatoms is used, then GPR40 activity is achieved, but selectivity against PPAR gamma is reduced
Solution Approach 1:
Instead of following the conventional approach of using pure hydrocarbon spiro groups, the patent inverts the strategy by incorporating heteroatoms into the spiro structure. This inversion achieves the opposite effect: enhanced PPAR gamma selectivity while maintaining GPR40 activity, thereby improving receptor discrimination through counterintuitive structural design.
Data Source
AI summary
A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.